Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The c-MYC messenger RNA 3′ untranslated region (UTR) contains specific poly-uridine (poly-U) or U-rich elements that serve as critical regulatory hubs for gene expression. These elements, often categorized as adenylate-uridylate-rich elements (AREs), are recognized by various RNA-binding proteins (RBPs) such as HuR (ELAVL1) and AUF1, which dictate the stability and translational efficiency of the c-MYC transcript (PubMed: 10487760). In healthy cells, these elements ensure the rapid turnover of c-MYC mRNA, preventing the overproduction of the MYC transcription factor, which is a potent driver of cell proliferation and survival. However, in many cancers, the regulation of these elements is subverted, leading to the stabilization of c-MYC mRNA and subsequent oncogenic protein overexpression (Nature Reviews Cancer, 2012). Targeting these poly-U elements or their associated RBPs represents a therapeutic strategy to downregulate MYC in tumors where it is otherwise considered undruggable at the protein level. Experimental approaches include small molecules that disrupt RNA-protein complexes and antisense oligonucleotides designed to block these regulatory sites (Journal of Biological Chemistry, 2014). Successfully modulating these elements can induce apoptosis and cell cycle arrest in MYC-dependent cancer cells.
Modulation of mRNA degradation rate, inhibition of protein translation, and disruption of RNA-binding protein (RBP) interactions to reduce oncogenic protein expression.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on c-MYC messenger RNA 3′ untranslated region poly-uridine elements (c-MYC mRNA 3′ UTR poly-U elements).